Grade My Investments
HomeFree Stock Grades › STXS

Stereotaxis, Inc. (STXS) Stock Grade

STXS · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$209.2M
P/E Ratio
Revenue Growth (YoY)
+20.3%
Net Margin
-66.9%
Return on Equity
Dividend Yield
None

About Stereotaxis, Inc.'s fundamentals

Stereotaxis is a small-cap healthcare company with a $209.2 million market capitalization that reported strong revenue growth of 20.3% year-over-year, indicating expanding demand for its medical equipment and services. However, the company is currently unprofitable, posting a net loss with a negative net margin of -66.9%, meaning it spent significantly more than it earned during its latest fiscal year. The company does not pay a dividend, which is typical for loss-making businesses focused on reinvestment and growth.

Track STXS free — no credit card required. Live grade + monthly AI report →